Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium Lu 177 XT117

A radioconjugate composed of XT117, a fibroblast activation protein inhibitor (FAPi), conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against FAP-expressing cancer-associated fibroblasts (CAFs). Upon administration, lutetium Lu 177 XT117 targets and binds to FAP-expressing CAFs. Upon binding, FAP-expressing CAFs are destroyed by 177Lu through the specific delivery of beta particle radiation. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME) of various cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[177Lu]Lu-XT117
177Lu-labeled XT117
Lu-177-XT117
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search